HomeMarket News Exciting News: Novo Nordisk's Ozempic Demonstrates Kidney Disease Progression Reduction ...

Exciting News: Novo Nordisk’s Ozempic Demonstrates Kidney Disease Progression Reduction Novo Nordisk’s Ozempic Shows Promise in Reducing Kidney Disease Progression

Actionable Trade Ideas

always free

Ozempic 2

On Tuesday, Novo Nordisk A/S NVO unveiled the headline results from the kidney outcomes trial, FLOW.

The study compared injectable semaglutide 1.0 mg with placebo to assess kidney outcomes for individuals with type 2 diabetes and chronic kidney disease (CKD).

With 3,533 participants, the trial enrolled individuals with type 2 diabetes and CKD.

In October 2023, the FLOW trial was halted by Novo Nordisk based on the Data Monitoring Committee’s recommendation.

Also Read: Obesity Solutions Like Weight Loss Drugs To Act As Catalyst For Economic Surge, Goldman Sachs Forecasts.

The trial met its primary endpoint, showing a 24% reduction in kidney disease progression, major adverse cardiovascular events, and death in participants taking semaglutide 1.0 mg compared to the placebo.

The primary endpoint comprised five elements measuring CKD progression and the risk of kidney and cardiovascular mortality.

The components related to CKD and cardiovascular aspects significantly contributed to the risk reduction.

Semaglutide 1.0 mg demonstrated a safe and well-tolerated profile throughout the trial, aligning with previous studies on the drug.

Novo Nordisk anticipates submitting applications for Ozempic’s label expansion in the U.S. and EU in 2024.

Known as Ozempic, the once-weekly subcutaneous semaglutide is available in 0.5 mg, 1.0 mg, and 2.0 mg doses. It is indicated as an adjunct to diet and exercise for type 2 diabetes and for reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.

Read Next: Novo Nordisk’s Weight Loss Drugs Ozempic, Wegovy Show Promise For Diabetic Patients Undergoing Hip Replacement.

Price Action: NVO shares are down 1.79% at $125.66 during the premarket session as of the latest check on Tuesday.

Image via Shutterstock

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.